FDA approval is the goal for product candidates from Daré Bioscience, Inc.
Steady: 1 development in the last 24 hours, 1 in the last 7 days
Updated yesterday
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approval is the goal for product candidates from Daré Bioscience, Inc.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.DARE-LARC1 is being developed for women's health, and the DARE-IDDS platform may extend to chronic disease markets.1 source
- NIAID provided a $2.0 million award for DARE-HPV, and the patent issuance expanded the IP foundation for the product.Sub-event
Pursuing 505(b)(2) regulatory pathway.1 source
Protocol amendment approval received for Ovaprene study.1 source
- Daré Bioscience, Inc. launched Flora Sync LF5™, marking its first consumer revenue stream.Sub-event
Daré Bioscience is pursuing FDA approval for its product candidates.1 source
Ovaprene requires FDA approval for market entry.1 source
Keep exploring
The entities involved
Related events
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA approval preceded a device showcase event held in Las Vegas on October 13, 2026.
- FDA approval supports NDA submission in Aurora.
- Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.
Coverage
Newest first; wire copies grouped- manilatimes.net
- manilatimes.net
- themarketsdaily.com
- GlobeNewswireDaré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NA
- GlobeNewswirePositive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive Interim Phase 3 Results Support Ovaprene’s Differentiation as a First-in-Category, Hormone-Free, In
- GlobeNewswireDaré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Po